Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : MAPS
Deal Size : $0.2 million
Deal Type : Funding
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial
Details : The funding will be used for a pilot study examining 3,4-methylenedioxymethamphetamine (MDMA)-assisted massed exposure therapy for post-traumatic stress disorder.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : MAPS
Deal Size : $0.2 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?